Clinical Trial Update: Immunogenicity and Safety Study of 1 and 2 Doses of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine MenACWY-TT (GSK134612) in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer's Prevenar 13™Vaccine [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating immunogenicity and safety of 1- and 2-dose regimens of MenACWY-TT (GSK134612) in toddlers, with persistence up to 5 years and co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease
• Meningococcal Infections in Toddlers

Drugs mentioned

• MenACWY-TT (GSK134612) (meningococcal conjugate vaccine)
• Prevenar 13 (Pneumococcal conjugate vaccine (13-valent))

Snippet

Sponsor: Pfizer | Conditions: Infections, Meningococcal | Phase 3 | Status: COMPLETED | Results posted: 2021-10-05